Floatz logo

Therapeutic Asset Ratings

195 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Imlunestrant
Localized Human Epidermal Growth Factor Receptor (HER2)-Negative Breast Carcinoma
Jonsson Comprehensive Cancer CenterP2CCC (53)
lutetium (<sup>177</sup>Lu) zadavotide guraxetan
Oligometastatic Prostate Carcinoma
Jonsson Comprehensive Cancer CenterP2CCC (53)
lutetium (<sup>177</sup>Lu) zadavotide guraxetan
Prostate Cancer
Jonsson Comprehensive Cancer CenterP2CCC (53)
lutetium (<sup>177</sup>Lu) zadavotide guraxetan
Stage IVB Prostate Cancer AJCC v8
Jonsson Comprehensive Cancer CenterP2CCC (53)
Pamiparib
Clear Cell Papillary Renal Neoplasm
Jonsson Comprehensive Cancer CenterP2CCC (53)
Pamiparib
Collecting Duct Carcinoma
Jonsson Comprehensive Cancer CenterP2CCC (53)
Pamiparib
Hereditary Leiomyomatosis and Renal Cell Carcinoma
Jonsson Comprehensive Cancer CenterP2CCC (53)
Pamiparib
Hereditary Papillary Renal Cell Carcinoma
Jonsson Comprehensive Cancer CenterP2CCC (53)
Pamiparib
Metastatic Renal Cell Carcinoma
Jonsson Comprehensive Cancer CenterP2CCC (53)
Pamiparib
Metastatic Unclassified Renal Cell Carcinoma
Jonsson Comprehensive Cancer CenterP2CCC (53)
Pamiparib
Papillary Renal Cell Carcinoma
Jonsson Comprehensive Cancer CenterP2CCC (53)
Pamiparib
Tubulocystic Renal Cell Carcinoma
Jonsson Comprehensive Cancer CenterP2CCC (53)
Zirconium Zr 89 girentuximab deferoxamine
Sarcomatoid Renal Cell Carcinoma
Jonsson Comprehensive Cancer CenterP2CCC (53)
FLUDEOXYGLUCOSE
Malignant Solid Neoplasm
Jonsson Comprehensive Cancer CenterP1/2CCC (53)
Arimidex
Endometrial Cancer
Jonsson Comprehensive Cancer CenterP2CCC (52)
Cediranib
Invasive Breast Carcinoma
Jonsson Comprehensive Cancer CenterP1CCC (52)
BMS-986345
T-cell Prolymphocytic Leukemia
Jonsson Comprehensive Cancer CenterP1/2CCC (52)
Duvelisib
T-cell Prolymphocytic Leukemia
Jonsson Comprehensive Cancer CenterP1/2CCC (52)
lutetium (<sup>177</sup>Lu) zadavotide guraxetan
Prostate Adenocarcinoma
Jonsson Comprehensive Cancer CenterP2CCC (51)
Tocilizumab
Recurrent Diffuse Large B-Cell Lymphoma
Jonsson Comprehensive Cancer CenterP1/2CCC (51)
Necitumumab
Stage IV Lung Cancer AJCC v8
Jonsson Comprehensive Cancer CenterP1/2CCC (50)
Venetoclax
T-cell-prolymphocytic Leukemia
Jonsson Comprehensive Cancer CenterP1/2CCC (48)
Cyclophosphamide
Adult Solid Neoplasm
Jonsson Comprehensive Cancer CenterP1CC (47)
Fludarabine
CD20 Positive
Jonsson Comprehensive Cancer CenterP1CC (47)
Duvelisib
Cutaneous T-Cell Lymphoma Refractory
Jonsson Comprehensive Cancer CenterP1/2CC (47)
Showing 76 to 100 of 195 assets
PreviousPage 4 of 8Next